Estuary Launches With $103M for Kidney Gene Therapy

Estuary Biotherapeutics has emerged from stealth with $103 million to pursue a difficult goal: treating inherited kidney disease at its genetic source rather than only slowing its progression.

What happened

The financing comprises a new $93 million Series A plus an earlier $10 million seed round, bringing Estuary's total committed capital to $103 million. The Series A was led by RA Capital Management, with participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises and Pivotal bioVenture Partners.

Estuary is developing two preclinical AAV gene therapies, EST-201 and EST-101, for autosomal dominant polycystic kidney disease. The condition is commonly caused by mutations affecting PKD1 or PKD2 and can lead to progressive cyst growth, kidney enlargement and eventual loss of kidney function. The company plans to use the funding to move both programmes toward clinical proof of concept.

Why it matters

Existing treatment can slow the disease, but it does not correct the underlying genetic defect. Estuary is attempting to restore the affected proteins directly in kidney cells, which could change the treatment model if it works safely in humans.

The important caveat is that both programmes remain preclinical. Delivering gene therapies effectively to kidney tissue is technically demanding, and claims about halting or reversing disease still require human evidence.

The bigger picture

The round shows that specialist investors remain willing to fund ambitious gene therapies when the target is genetically clear and the unmet need is large. It also gives Estuary enough capital to test whether AAV technology can move beyond better-established organs and become practical in the kidney.